Research Topics
| John SullivanSummaryAffiliation: University of Massachusetts Medical School Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Genotypic and functional properties of early infant HIV-1 envelopesMichael Kishko
Graduate School of Biomedical Sciences, University of Massachusetts Medical School, Worcester, MA, USA
Retrovirology 8:67. 2011..Following extensive genotypic and phylogenetic analyses, 35 representative clones were selected for functional studies...- Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USAMarie Louise Newell
Centre of Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, UK
BMC Infect Dis 7:60. 2007.... 
Prevention of mother-to-child transmission of HIV--what next?John L Sullivan
Department of Pediatrics and Molecular Medicine, University Massachusetts Medical School, Worcester, MA 01655, USA
J Acquir Immune Defic Syndr 34:S67-72. 2003..However, a number of issues remain to be resolved, particularly methods to reduce the transmission of the virus during breastfeeding and to deliver effective treatment for the mothers' own HIV infection...- The abnormal gene in X-linked lymphoproliferative syndromeJ L Sullivan
Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Biotech II, Suite 318, Worcester, MA 01605, USA
Curr Opin Immunol 11:431-4. 1999.... - Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohortT C Greenough
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
J Infect Dis 180:1790-802. 1999..The presence of expanded, activated CD8 T cells with cytotoxic effector function in the peripheral blood suggests ongoing viral replication... - Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responsesK Luzuriaga
Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
J Virol 74:6984-91. 2000..These results are consistent with the notion that early combination antiretroviral therapy of HIV-1-infected infants allows the long-term suppression of viral replication... - Dynamics of human immunodeficiency virus type 1 replication in vertically infected infantsK Luzuriaga
Department of Pediatrics, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Boston, Massachusetts, USA
J Virol 73:362-7. 1999..These data confirm the central role of HIV-1 replication in the pathogenesis of vertical HIV-1 infection and reinforce the importance of early, potent combination therapies for the long-term control of HIV-1 replication... - Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infantsZ A Scott
Graduate Program in Immunology/Virology and Department of Pediatrics and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
J Immunol 167:7134-40. 2001..Therapeutic HIV-1 vaccine strategies in young infants may prolong the clinical benefit of ART by expanding the HIV-1-specific CD8(+) T cell pool... - Viral and immunopathogenesis of vertical HIV-1 infectionK Luzuriaga
Department of Pediatrics, University of Massachusetts Medical School, Worcester, USA
Pediatr Clin North Am 47:65-78. 2000.... - Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesinR A Koup
University of Massachusetts Medical School, Department of Pediatrics, Worcester
AIDS 7:1181-4. 1993..To determine whether synergistic inhibition of HIV-1 replication would result from the in vitro use of nevirapine in combination with zidovudine, interferon (IFN)-alpha 2C, and CD4 immunoadhesin... - Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1R A Koup
Department of Pediatrics, University of Massachusetts Medical School, Worcester
AIDS 5:1309-14. 1991..15e defines an important epitope in the human immune response to HIV-1 infection. Antibodies with 15e-like activity may be useful in immunoprophylaxis or immunotherapy of HIV-1 infection... - High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid miceR M Hesselton
Department of Pediatrics, University of Massachusetts Medical School, Worcester, USA
J Infect Dis 172:974-82. 1995..B-17-scid/scid mice. The NOD/LtSz-scid/scid mouse may provide a useful small animal model for studies of HIV-1... - Accuracy of the TRUGENE HIV-1 genotyping kitRobert M Grant
Gladstone Institute of Virology and Immunology, San Francisco, CA 94141, USA
J Clin Microbiol 41:1586-93. 2003..This integrated assay system for the detection of HIV-1 drug resistance mutations has a high degree of accuracy and reproducibility in several laboratories... - Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in miceThomas C Greenough
Department of Pediatrics, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 02130, USA
J Infect Dis 191:507-14. 2005..Antibodies to both epitopes protected mice against SARS-CoV challenge. Clinical trials are planned to test MAb 201, a fully human MAb specific for the epitope within the receptor-binding region... - Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2Wenhui Li
Partners AIDS Research Center, 65 Landsdowne St, Cambridge, MA 02139, USA
J Virol 78:11429-33. 2004..These data imply that a mouse transgenically expressing human ACE2 may be a useful animal model of SARS... - The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316Coleen K Cunningham
Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
J Acquir Immune Defic Syndr 36:800-7. 2004..Race/ethnicity is significant in predicting viral suppression at the time of delivery... - A trial of three antiretroviral regimens in HIV-1-infected childrenKatherine Luzuriaga
Department of Pediatrics and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Mass 01605, USA
N Engl J Med 350:2471-80. 2004..Depletion of CD4 T-cell counts or progression of human immunodeficiency virus (HIV) disease occurs rapidly in children, but few data address the efficacy of aggressive therapy for HIV-infected children... - Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirusThomas C Greenough
Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01605, USA
Am J Pathol 167:455-63. 2005..These findings identify the common marmoset as a promising nonhuman primate to study SARS-CoV pathogenesis... - Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamstersAnjeanette Roberts
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
J Infect Dis 193:685-92. 2006.... - Pediatric HIV-1 infection: advances and remaining challengesKatherine Luzuriaga
University of Massachusetts Medical School, Department of Pediatrics, Program in Molecular Medicine, 373 Plantation Street, Biotech II Suite 318, Worcester, MA 01605, USA
AIDS Rev 4:21-6. 2002..Continued efforts to understand MTCT and pediatric HIV-1 pathogenesis and to refine preventive and therapeutic strategies are of high priority... - Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine doseMark Mirochnick
Boston University School of Medicine, Boston Medical Center, 91 Concord Street, 6th Floor, Boston, MA 02118, USA
J Acquir Immune Defic Syndr 33:153-6. 2003..To evaluate cord blood and predose nevirapine concentrations in infants exposed to the two-dose intrapartum neonatal nevirapine regimen... - Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stabilityDon Brambilla
New England Research Center, Waltham, Massachusetts, USA
J Clin Microbiol 41:1888-93. 2003..Dried blood and dried plasma spots can be used as an easy and inexpensive means for the collection and storage of specimens under field conditions for the diagnosis of HIV infection and the monitoring of antiretroviral therapy... - Enhanced culture method for detection of replication-competent virus in peripheral blood mononuclear cells of HIV type 1-infected individualsJohn P Haran
Department of Pediatrics and Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605
AIDS Res Hum Retroviruses 18:577-83. 2002..This will be a useful technique by which to study viral latency and HIV-1 pathogenesis in adult and pediatric populations... - A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1Dhayendre Moodley
Department of Obstetrics and Gynaecology, Paediatrics and Child Health, Nelson R Mandela School of Medicine, University of Natal, KwaZulu Natal, Congella 4013, South Africa
J Infect Dis 187:725-35. 2003..3%; Zdv/3TC group, 26.3%) and respiratory for infants (Nvp group, 16.1%; Zdv/3TC group, 17.0%). This study further confirms the efficacy and safety of short-course ARV regimens in reducing MTCT rates in developing countries... - Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical prioritiesKatherine Luzuriaga
University of Massachusetts Medical School, Program in Molecular Medicine, 373 Plantation Street, Suite 318, Worcester, MA 01605, USA
Lancet 368:511-21. 2006..Here, we discuss the scientific and logistical challenges for the development of paediatric HIV vaccines; available vaccines and completed or planned paediatric vaccine trials are also discussed... - Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3Coleen K Cunningham
Department of Pediatrics, State University of New York Upstate Medical University, Syracuse, Syracuse, NY 13210, USA
J Infect Dis 186:181-8. 2002..The risk of nevirapine resistance should be considered when determining the risks or benefits of intrapartum nevirapine in women receiving antepartum antiretroviral therapy... - Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trialAlejandro Dorenbaum
Department of Pediatrics, University of California, San Francisco, USA
JAMA 288:189-98. 2002..CONCLUSION: Risk of perinatal HIV transmission was low and no benefit from additional intrapartum/newborn nevirapine was demonstrated when women received prenatal care and antenatal ART, and elective cesarean section was made available... - Prevention of mother-to-child transmission of HIV infectionKatherine Luzuriaga
Clin Infect Dis 40:466-7. 2005 - Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuationMelissa A Farrow
Program in Molecular Medicine and Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
AIDS Res Hum Retroviruses 21:565-74. 2005..Our data highlight the importance of Vif in HIV-1 pathogenesis and also provide a unique tool to investigate the interaction of Vif and Apobec3G... - Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cellsDonna Hochberg
Department of Pathology, Jaharis Building, Tufts University School of Medicine, 150 Harrison Avenue, Boston, MA 02111, USA
J Virol 78:5194-204. 2004..This phase is followed by a slower decline that, even by 1 year, had not reached a steady state. Therefore, EBV may approach but never reach a stable equilibrium... - Alterations in HIV-1 LTR promoter activity during AIDS progressionKirsten Hiebenthal-Millow
Institute for Clinical and Molecular Virology, , Schlossgarten 4, 91054 Erlangen, Germany
Virology 317:109-18. 2003..Our findings show that in a subset of HIV-1-infected individuals enhanced LTR transcription contributes to the increased replicative potential of late stage virus isolates and might accelerate disease progression... - Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusWenhui Li
Partners AIDS Research Center, Brigham and Women s Hospital, Department of Medicine Microbiology and Molecular Genetics, Boston, Massachusetts 02115, USA
Nature 426:450-4. 2003..Finally, anti-ACE2 but not anti-ACE1 antibody blocked viral replication on Vero E6 cells. Together our data indicate that ACE2 is a functional receptor for SARS-CoV... - Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infectionMelissa L Precopio
Graduate Program in Immunology/Virology, University of Massachusetts Medical School, Worcester, MA 01605, USA
J Immunol 170:2590-8. 2003..Peripheral blood EBV load directly correlated with the frequency of EBV-specific CD4(+) T cell responses at presentation and over time, suggesting that EBV-specific CD4(+) T cell responses are Ag-driven... - Concentrations of protease inhibitors in cord blood after in utero exposureMark Mirochnick
Boston University School of Medicine, and Statistical and Data Analysis Center/Harvard School of Public Health, Boston, MA, USA
Pediatr Infect Dis J 21:835-8. 2002..CONCLUSIONS: Low protease inhibitor concentrations in the fetus decrease the likelihood of teratogenic and toxic effects of these drugs but could fail to provide protection from transplacental or intrapartum transmission of HIV-1... - Evidence for a cytopathogenicity determinant in HIV-1 VprMohan Somasundaran
Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, MA 01605, USA
Proc Natl Acad Sci U S A 99:9503-8. 2002..This study suggests the presence of a determinant of in vivo cytopathogenicity within HIV-1 Vpr and further indicates that viral replication can be uncoupled from cytopathicity in vitro and in vivo...
Research Grants
- Quality Improvement through Electronic EnhancementsJohn Sullivan; Fiscal Year: 2003..abstract_text> ..
- EXPANSION AND CENTRALIZATION OF AQUATIC ANIMAL HOUSINGJohn Sullivan; Fiscal Year: 2004..The requested basic research equipment will be used by both zebrafish and Xenopus users and will significantly augment UMMS aquatic animal research. ..
- Quality Improvement in Human Subjects ResearchJohn Sullivan; Fiscal Year: 2002..Acknowledging that UMMS is dedicated to expanding our capacity for human subjects protection, there is a strong institutional commitment to continue these efforts beyond this one-year IRB enhancement funding. ..
- IMMUNOREGULATORY DEFECTS IN HEMOPHILIAJohn Sullivan; Fiscal Year: 2001..These studies should further our understanding of HIV-1 specific cell-mediated immunity and provide new information which will be useful in the development of an effective vaccine for the prevention of HIV-1 infection. ..
- IMMUNOREGULATORY DEFECTS IN HEMOPHILIAJohn Sullivan; Fiscal Year: 1993..They will also contribute important information as to the clinical significance of the immune deficits and the effect on the immune system of alternative forms of factor replacement in classic hemophilia...
- UMMS Clinical and Translational ScienceJohn Sullivan; Fiscal Year: 2006....